Results 141 to 150 of about 815,023 (339)
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
A Study on Dynamic Modulus of Epoxy Asphalt Concrete: Experiment and Modeling
Journal of Materials and Engineering StructuresEpoxy asphalt concrete (EAC) has been applied as a surface layer for heavy-load pavements and as a coating layer on steel bridge decks in many countries such as Japan, the UK and the US.
Thi Cam Ha TRAN, Danh Hoi TRAN
doaj
Master curve evaluation of ANP-5 steel using mini-CT specimens
, 2022 Marcos Sánchez +3 more
openalex +1 more source
Non-Destructive Testing in Concrete Maturity Modeling and Master Curve Development [PDF]
, 2023 Setare Ghahri Saremi, Dimitrios Goulias
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Applications of Master Cooling Curve
Tetsu-to-Hagane, 1974 Yoshio TOKIHIRO, Imao TAMURA
openaire +2 more sources
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source